[Form 4] Bio-Techne Corp. Insider Trading Activity

Rhea-AI Filing Summary

Amy E. Herr, a director of Bio-Techne Corp (TECH), reported multiple transactions dated 08/15/2025 affecting both her direct and indirect holdings. The filing shows disposals of 1,040 shares (reported as a direct disposition) and 101 shares sold at $53.60 (reported as indirect, by significant other). The report also records a non-cash acquisition of 279 shares (transaction code M) at $0 and various option and restricted stock unit holdings and vesting schedules. After the reported transactions, beneficial ownership totals are shown as 2,255 and 2,154 shares in different lines, with numerous outstanding stock options and RSUs exercisable or vesting through 2035.

Positive

• Detailed vesting schedules disclosed for options and RSUs through 2035, improving transparency
• Non-cash issuance recorded (279 shares, code M), indicating grant/award rather than market purchase
• Significant remaining long-term equity alignment via multiple options and RSUs exercisable/vesting over several years

Negative

• Dispositions of common stock including a 1,040-share sale and a 101-share sale at $53.60, which reduce insider holdings
• Some holdings are indirect (by significant other), complicating direct attribution of ownership and potential signaling

Insights

Securities Analyst

TL;DR: Insider reported routine sales and continued significant equity-linked compensation holdings through 2035.

The Form 4 documents both cash sales and non-cash acquisitions for a board director. The 101-share sale at $53.60 is priced and explicit; the larger 1,040-share disposition lacks an indicated price in the provided lines. Multiple stock options and restricted stock units remain outstanding with staggered vesting dates through 2035, indicating ongoing alignment with long-term equity compensation programs rather than a single opportunistic event. The filings list indirect ownership attributable to a significant other for several holdings, which affects aggregation of family-held economic exposure.

Corporate Governance Expert

TL;DR: Disclosure is detailed and includes vesting schedules, supporting transparency around director compensation.

The Form 4 provides granular vesting schedules for options and RSUs, including fully vested grants and future vesting through 2035. This level of detail supports transparency on potential future share issuances to insiders. The combination of immediate sales and retained long-term instruments is consistent with scheduled liquidity and compensation realization; the filing does not present explicit material governance concerns based on the transactions disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Herr Amy E.

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								1,040	D
Common Stock	08/15/2025		M		279	A	$0	2,255	I	By significant other
Common Stock	08/15/2025		F		101	D	$53.6	2,154	I	By significant other

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$72.05							(1)	02/03/2035	Common Stock	2,415		2,415	D
Stock Option (Right to Buy)	$47.6							(2)	08/07/2026	Common Stock	6,636		6,636	I	By significant other
Stock Option (Right to Buy)	$66.97							(2)	08/05/2027	Common Stock	4,472		4,472	I	By significant other
Stock Option (Right to Buy)	$120.46							(3)	08/06/2028	Common Stock	2,076		2,076	I	By significant other
Stock Option (Right to Buy)	$94.52							(4)	08/15/2029	Common Stock	2,104		2,104	I	By significant other
Stock Option (Right to Buy)	$84.61							(5)	08/15/2030	Common Stock	1,084		1,084	I	By significant other
Stock Option (Right to Buy)	$74.91							(6)	08/15/2034	Common Stock	1,468		1,468	I	By significant other
Stock Option (Right to Buy)	$72.05							(7)	02/03/2035	Common Stock	344		344	I	By significant other
Restricted Stock Units	(8)	08/15/2025		M			119	(9)	(9)	Common Stock	119	$0	118	I	By significant other
Restricted Stock Units	(8)	08/15/2025		M			160	(10)	(10)	Common Stock	160	$0	320	I	By significant other
Restricted Stock Units	(8)							(11)	(11)	Common Stock	115		115	I	By significant other
Restricted Stock Units	(8)	08/15/2025		A		932		(12)	(12)	Common Stock	932	$0	932	I	By significant other
Stock Option (Right to Buy)	$53.6	08/15/2025		A		2,735		(13)	08/15/2035	Common Stock	2,735	$0	2,735	I	By significant other

Explanation of Responses:

1. This option vests on the earlier of the one-year anniversary of the grant date (2/3/2025) or the date of Bio-Techne's 2025 annual meeting of shareholders.

2. Fully vested.

3. Options to purchase 520 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2025; and options to purchase 516 shares vest on 8/6/2024.

4. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.

5. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.

6. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

7. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.

8. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

9. 119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026.

10. 160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.

11. 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028.

12. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.

13. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.

	/s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Amy E. Herr report in the 08/15/2025 Form 4 for TECH?

The filing reports dispositions of 1,040 shares (direct), a sale of 101 shares at $53.60 (indirect), a non-cash acquisition of 279 shares (code M), and numerous stock options and RSUs with vesting dates through 2035.

How many stock options and RSUs does the Form 4 show for TECH?

The filing lists multiple option grants and RSUs totaling several thousand underlying shares, including exercisable/options amounts of 2,415, 6,636, 4,472, and additional grants, plus RSUs of 119, 160, 115, and 932 in various lines.

Are any of the option grants fully vested according to the filing?

Yes. The filing indicates certain grants are fully vested (noted in the explanation as fully vested).

Do any transactions indicate purchases at market price?

The only sale with an explicit price in the provided content is the 101-share sale at $53.60; other dispositions either show no price or are coded as non-cash grants.

Who signed the Form 4 filing for Amy E. Herr?

The form is signed by Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to a previously filed power of attorney on 08/19/2025.